A Phase 2 interventional study of NAL ER and Placebo in Refractory Chronic Cough, sponsored by Trevi Therapeutics. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Trevi Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Chronic Cough with a site in United Kingdom — 4 open to participants now, 6 under way, 1 of them phase 3. Chronic Cough · United Kingdom.
Among the 36 studies in Chronic Cough with a site in United Kingdom, this one is the 18th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2023, is one of 15 in phase 2, and was the 29th registered.
142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.
Browse Chronic Cough studies →4 of the 36 studies in Chronic Cough with a site in United Kingdom are open now. Recruiting first, the newest first:
Sensory Cloud, Inc. · Sites in United Kingdom
Ages 18–80
Trevi Therapeutics · Sites in United Kingdom, Canada
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 30–70 · Healthy volunteers
Hull University Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 7 · Phase 4 2
First in 2008; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 100 across the 29 interventional studies, 60 across the 7 observational. Of the 27 that completed or were terminated, 12 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
Trevi Therapeutics is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Trevi Therapeutics has 2 studies filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Cough with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07690059Sensory Cloud, Inc.A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough | 2027-01 |
| NCT07671924Trevi TherapeuticsThe Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Chronic Cough with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.
Key Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received NAL ER at escalating doses (27 mg QD to BID, 54 mg BID, and 108 mg BID) in Treatment Period 1, followed by placebo matched to NAL ER in Treatment Period 2.
Drug: NAL ER · Drug: Placebo
Participants received placebo matched to NAL ER in Treatment Period 1, followed by NAL ER at escalating doses (27 mg QD to BID, 54 mg BID, and 108 mg BID) in Treatment Period 2.
Drug: NAL ER · Drug: Placebo
Oral tablets
Also known as: Nalbuphine
Oral tablets
Relative Change From Baseline in 24-hour Cough Frequency at Day 21
Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.
Time frame: Baseline, Day 21
Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
Time frame: Up to Week 15
Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments
The clinical laboratory parameters included urinalysis, hematology, serum chemistry and coagulation. Clinical significance was determined by the investigator.
Time frame: Up to Week 15
Number of Participants With Clinically Significant Changes in Vital Sign Parameters
Vital signs measurements included blood pressure, heart rate, respiration rate, body temperature, pulse oximetry, and weight. Clinical significance was determined by the investigator.
Time frame: Up to Week 15
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
Changes in ECG data such as heart rate, rhythm, and other clinically significant abnormalities (left ventricular hypertrophy, pathological Q-waves) were measured. Clinical significance was determined by the investigator.
Time frame: Up to Week 15
Number of Participants With Clinically Significant Changes in Physical Examination Parameters
Physical examination included examination of the following body systems: general appearance, eyes, ears, nose, throat, head and neck, chest and lungs, cardiovascular, abdomen, musculoskeletal, lymphatic, dermatological, neurological, and extremities. Clinical significance was determined by the investigator.
Time frame: Up to Week 15
Relative Change From Baseline in 24-hour Cough Frequency at Days 7 and 14
Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.
Time frame: Baseline, Days 7 and 14
Percentage of Responders With >=30%, 50% and 75% Reduction in 24-hour Cough Frequency
Responders were defined as those with ≥30%, ≥50%, or ≥75% reduction in 24-hour cough frequency from Baseline at Days 7, 14, or 21.
Time frame: Days 7, 14, and 21
Relative Change From Baseline in Awake Cough Frequency at Days 7, 14, and 21
Awake cough was defined as cough that occurs between the time that the participant is awaken 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.
Time frame: Baseline, Days 7, 14, and 21
Relative Change From Baseline in Sleep Cough Frequency at Days 7, 14, and 21
Sleep cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.
Time frame: Baseline, Days 7, 14 and 21
Change From Baseline in Cough Severity Visual Analogue Scale (CS-VAS) at Days 7, 14, and 21
The CS-VAS is a brief, easily administered patient reported outcome (PRO) questionnaire that is used to assess cough severity in both acute and chronic cough. CS-VAS is a 1-item scale that rates the severity of participants' cough from 0 millimeter (mm) where 0 indicated "no cough" and 100 represented "worst cough ever". A negative change from baseline indicates improvement.
Time frame: Baseline, Days 7, 14, and 21
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Day 21
LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status.
Time frame: Baseline, Day 21
Change From Baseline in Patient-Reported Cough Frequency (PR-CF) at Days 7, 14, and 21
Patient-Reported Cough Frequency (PR-CF) is a daily, self-reported, 1 item scale, PRO that is used to assess cough frequency. Participants rate their cough frequency over the past 24 hours using a 5-point Likert scale (0- to 4: 0 = Not at all, 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
Time frame: Baseline, Days 7, 14, and 21
Percentage of PR-CF Responders With at Least One Category Improvement at Days 7, 14, and 21
PR-CF is a daily, self-reported, 1 item scale, PRO that is used to assess cough frequency. Participants rate their cough frequency over the past 24 hours using a 5-point Likert scale (0 to 4: 0 = Not at all, 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly). A higher score indicates more severe symptoms. PR CF responders were defined as participants with at least a one category improvement at Days 7, 14, and 21.
Time frame: Days 7, 14, and 21
Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough at Days 7, 14, and 21
The PGI-S Cough scale is a self-reported, single-item categorical scale that is increasingly used when assessing chronic cough. Participants rate the severity of their cough in the last week with a 4-point Likert scale ranging from 0 to 3 (0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
Time frame: Baseline, Days 7, 14 and 21
Patient Global Impression of Change for Cough (PGI-C) Score at Days 7, 14, and 21
The PGI-C Cough scale is a self-reported, single-item categorical scale that is increasingly used when assessing chronic cough. Participants rate the severity of their cough in the last week with a 7-point Likert scale ranging from 0 to 7 (0 = No Cough, 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, or 7 = Much worse). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
Time frame: Days 7, 14, and 21
Change From Baseline in Clinicians Global Impression of Cough Severity Score (CGI-S) at Day 21
The CGI-S Cough scale is an investigator-reported, single-item categorical scale that is increasingly used when assessing the severity of the condition. Investigator rate the severity of their cough in the last week with a 4-point Likert scale ranging from 0 to 3 (0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
Time frame: Baseline, Day 21
Clinicians Global Impression of Change for Cough Score (CGI-C) at Day 21
The PGI-C Cough scale is an investigator-reported, single-item categorical scale that is increasingly used when assessing the investigator's belief of the participant's overall improvement pre-treatment baseline. Investigator rate the change in improvement in the last week with a 7-point Likert scale ranging from 1 to 7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6= Much worse, or 7= Very much worse). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
Time frame: Day 21
Participants were enrolled at 14 sites from 30 November 2023 to 06 January 2025.
| Milestone | First NAL ER Then Placebo | First Placebo Then NAL ER |
|---|---|---|
| Started | 34 | 32 |
| Full analysis set (fas) | 30 | 29 |
| Completed | 28 | 29 |
| Not completed | 6 | 3 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Milestone | First NAL ER Then Placebo | First Placebo Then NAL ER |
|---|---|---|
| Started | 28 | 29 |
| Completed | 28 | 29 |
| Not completed | 0 | 0 |
| Milestone | First NAL ER Then Placebo | First Placebo Then NAL ER |
|---|---|---|
| Started | 28 | 29 |
| Completed | 27 | 24 |
| Not completed | 1 | 5 |
| Withdrew: Adverse event | 0 | 4 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Reason not specified | 0 | 1 |
Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.
| coughs per hour | NAL ER | Placebo |
|---|---|---|
| Relative Change From Baseline in 24-hour Cough Frequency at Day 21 | -64.92 ± 36.552 | -9.36 ± 40.952 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
| Participants | NAL ER | Placebo |
|---|---|---|
| Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs) | 50 | 32 |
The clinical laboratory parameters included urinalysis, hematology, serum chemistry and coagulation. Clinical significance was determined by the investigator.
| Participants | NAL ER | Placebo |
|---|---|---|
| Urinalysis | 0 | 0 |
| Hematology | 0 | 0 |
| Serum Chemistry | 1 | 1 |
| Coagulation | 0 | 0 |
Vital signs measurements included blood pressure, heart rate, respiration rate, body temperature, pulse oximetry, and weight. Clinical significance was determined by the investigator.
| Participants | NAL ER | Placebo |
|---|---|---|
| Blood Pressure | 11 | 4 |
| Heart Rate | 2 | 2 |
| Respiration Rate | 0 | 0 |
| Body Temperature | 0 | 0 |
| Pulse Oximetry | 0 | 0 |
| Weight | 2 | 0 |
Changes in ECG data such as heart rate, rhythm, and other clinically significant abnormalities (left ventricular hypertrophy, pathological Q-waves) were measured. Clinical significance was determined by the investigator.
| Participants | NAL ER | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) | 1 | 0 |
Physical examination included examination of the following body systems: general appearance, eyes, ears, nose, throat, head and neck, chest and lungs, cardiovascular, abdomen, musculoskeletal, lymphatic, dermatological, neurological, and extremities. Clinical significance was determined by the investigator.
| Participants | NAL ER | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Physical Examination Parameters | 10 | 12 |
Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.
| coughs per hour | NAL ER | Placebo |
|---|---|---|
| Change at Day 7 | -56.12 ± 30.733 | 7.70 ± 39.929 |
| Change at Day 14 | -59.20 ± 33.304 | -5.14 ± 40.457 |
Responders were defined as those with ≥30%, ≥50%, or ≥75% reduction in 24-hour cough frequency from Baseline at Days 7, 14, or 21.
| percentage of participants | NAL ER | Placebo |
|---|---|---|
| >=30% Reduction at Day 7 | 78.9 (66.1 to 88.6) | 14.5 (6.5 to 26.7) |
| >=30% Reduction at Day 14 | 76.4 (63.0 to 86.8) | 24.1 (13.5 to 37.6) |
| >=30% Reduction at Day 21 | 87.0 (75.1 to 94.6) | 30.2 (18.3 to 44.3) |
| >=50% Reduction at Day 7 | 63.2 (49.3 to 75.6) | 3.6 (0.4 to 12.5) |
| >=50% Reduction at Day 14 | 67.3 (53.3 to 79.3) | 11.1 (4.2 to 22.6) |
| >=50% Reduction at Day 21 | 79.6 (66.5 to 89.4) | 15.1 (6.7 to 27.6) |
| >=75% Reduction at Day 7 | 38.6 (26.0 to 52.4) | 0.0 (0.0 to 6.5) |
| >=75% Reduction at Day 14 | 41.8 (28.7 to 55.9) | 1.9 (0.0 to 9.9) |
| >=75% Reduction at Day 21 | 53.7 (39.6 to 67.4) | 1.9 (0.0 to 10.1) |
Awake cough was defined as cough that occurs between the time that the participant is awaken 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.
| coughs per hour | NAL ER | Placebo |
|---|---|---|
| Change at Day 7 | -54.17 ± 31.996 | 5.25 ± 37.779 |
| Change at Day 14 | -59.29 ± 32.437 | -5.01 ± 37.037 |
| Change at Day 21 | -64.96 ± 34.332 | -9.37 ± 39.322 |
Sleep cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.
| coughs per hour | NAL ER | Placebo |
|---|---|---|
| Change at Day 7 | -32.86 ± 198.036 | 53.24 ± 252.834 |
| Change at Day 14 | -7.11 ± 341.280 | 18.55 ± 165.295 |
| Change at Day 21 | -15.70 ± 244.516 | 30.11 ± 207.430 |
The CS-VAS is a brief, easily administered patient reported outcome (PRO) questionnaire that is used to assess cough severity in both acute and chronic cough. CS-VAS is a 1-item scale that rates the severity of participants' cough from 0 millimeter (mm) where 0 indicated "no cough" and 100 represented "worst cough ever". A negative change from baseline indicates improvement.
| millimeter | NAL ER | Placebo |
|---|---|---|
| Change at Day 7 | -22.2 ± 22.79 | -2.9 ± 13.82 |
| Change at Day 14 | -29.7 ± 22.72 | -4.1 ± 15.34 |
| Change at Day 21 | -29.9 ± 23.75 | -5.3 ± 15.96 |
LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Day 21 | 4.50 ± 3.818 | 0.25 ± 2.476 |
Patient-Reported Cough Frequency (PR-CF) is a daily, self-reported, 1 item scale, PRO that is used to assess cough frequency. Participants rate their cough frequency over the past 24 hours using a 5-point Likert scale (0- to 4: 0 = Not at all, 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Change at Day 7 | -0.74 ± 0.812 | 0.02 ± 0.685 |
| Change at Day 14 | -0.92 ± 0.763 | -0.13 ± 0.703 |
| Change at Day 21 | -1.08 ± 0.805 | -0.27 ± 0.811 |
PR-CF is a daily, self-reported, 1 item scale, PRO that is used to assess cough frequency. Participants rate their cough frequency over the past 24 hours using a 5-point Likert scale (0 to 4: 0 = Not at all, 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly). A higher score indicates more severe symptoms. PR CF responders were defined as participants with at least a one category improvement at Days 7, 14, and 21.
| percentage of participants | NAL ER | Placebo |
|---|---|---|
| Day 7 | 62.3 (47.9 to 75.2) | 18.0 (8.6 to 31.4) |
| Day 14 | 69.2 (54.9 to 81.3) | 27.1 (15.3 to 41.8) |
| Day 21 | 75.5 (61.7 to 86.2) | 34.7 (21.7 to 49.6) |
The PGI-S Cough scale is a self-reported, single-item categorical scale that is increasingly used when assessing chronic cough. Participants rate the severity of their cough in the last week with a 4-point Likert scale ranging from 0 to 3 (0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Change at Day 7 | -0.45 ± 0.601 | 0.06 ± 0.627 |
| Change at Day 14 | -0.84 ± 0.757 | -0.09 ± 0.564 |
| Change at Day 21 | -0.98 ± 0.751 | -0.09 ± 0.646 |
The PGI-C Cough scale is a self-reported, single-item categorical scale that is increasingly used when assessing chronic cough. Participants rate the severity of their cough in the last week with a 7-point Likert scale ranging from 0 to 7 (0 = No Cough, 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, or 7 = Much worse). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Day 7 | 2.64 ± 1.103 | 4.04 ± 1.213 |
| Day 14 | 2.41 ± 1.332 | 3.91 ± 1.229 |
| Day 21 | 2.07 ± 1.189 | 3.71 ± 1.066 |
The CGI-S Cough scale is an investigator-reported, single-item categorical scale that is increasingly used when assessing the severity of the condition. Investigator rate the severity of their cough in the last week with a 4-point Likert scale ranging from 0 to 3 (0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Change From Baseline in Clinicians Global Impression of Cough Severity Score (CGI-S) at Day 21 | -1.02 ± 0.700 | -0.36 ± 0.672 |
The PGI-C Cough scale is an investigator-reported, single-item categorical scale that is increasingly used when assessing the investigator's belief of the participant's overall improvement pre-treatment baseline. Investigator rate the change in improvement in the last week with a 7-point Likert scale ranging from 1 to 7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6= Much worse, or 7= Very much worse). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Clinicians Global Impression of Change for Cough Score (CGI-C) at Day 21 | 2.23 ± 0.934 | 3.50 ± 0.874 |
Collected over Up to Week 15. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NAL ER | 0/63 (0%) | 0/63 (0%) | 50/63 (79.4%) |
| Placebo | 0/59 (0%) | 0/59 (0%) | 32/59 (54.2%) |
| Event | NAL ER | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 18/63 | 4/59 |
| SomnolenceNervous system disorders | 16/63 | 0/59 |
| NauseaGastrointestinal disorders | 14/63 | 2/59 |
| DizzinessNervous system disorders | 12/63 | 2/59 |
| HeadacheNervous system disorders | 10/63 | 7/59 |
| FatigueGeneral disorders | 9/63 | 3/59 |
| VomitingGastrointestinal disorders | 6/63 | 1/59 |
| Dry mouthGastrointestinal disorders | 5/63 | 1/59 |
| NasopharyngitisInfections and infestations | 4/63 | 2/59 |
| DiarrhoeaGastrointestinal disorders | 3/63 | 3/59 |
The Safety Population consisted of all participants who had received at least one dose of NAL ER or Placebo.
| Age, Continuous(years) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| Mean | 63.0 ± 9.16 | 57.2 ± 11.08 | 60.2 ± 10.47 |
| Sex: Female, Male(Participants) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| Female | 23 | 21 | 44 |
| Male | 11 | 11 | 22 |
| Ethnicity (NIH/OMB)(Participants) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 34 | 32 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 31 | 30 | 61 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| 24-hour Cough Frequency(coughs per hour) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| Mean | 45.869 ± 54.7593 | 26.374 ± 24.8968 | 36.287 ± 43.5333 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Jan 2025, 13 months.
Results were first posted in Mar 2026, 1 year 2 months after primary completion.
Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 13 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalbuphine